IL-4 Fusion Toxin: Phase II

Preliminary MRI data from 22 treated patients in NBIX's Phase II trial showed that the compound produced changes suggestive of tumor necrosis (cell death). NBIX said that the compound was well tolerated, and that a maximum tolerated dose has been determined. The company expects the ongoing Phase II study to bridge into a Phase III trial in the first half of 2000.

Data were presented at the International Conference on Brain Tumor Research and Therapy in Hokkaido. ...